Welcome to our dedicated page for Avalo Therapeutics news (Ticker: AVTX), a resource for investors and traders seeking the latest updates and insights on Avalo Therapeutics stock.
Avalo Therapeutics, Inc. (NASDAQ: AVTX) is a clinical stage biotechnology company that regularly issues news and updates related to its focus on IL-1β-based treatments for immune-mediated inflammatory diseases. Company press releases consistently highlight progress with its lead asset, AVTX-009, a humanized monoclonal antibody targeting interleukin-1β (IL-1β), and its development in hidradenitis suppurativa (HS).
On this news page, readers can follow Avalo’s clinical development milestones, such as the design and execution of the Phase 2 LOTUS trial in adults with moderate to severe HS, completion of trial enrollment, and plans for future data readouts. The company’s releases describe the LOTUS trial as a randomized, double-blind, placebo-controlled Phase 2 study evaluating two AVTX-009 dosing regimens versus placebo, with HiSCR75 at Week 16 as the primary endpoint and several secondary HS disease activity and pain measures.
Avalo’s news flow also includes corporate and governance updates, including appointments of new board members and senior executives with backgrounds in clinical development, regulatory strategy, business development, finance and human resources. These announcements often describe related equity inducement grants and compensation arrangements, reflecting how the company structures incentives around its development priorities.
Investors and followers of AVTX can also find financial and capital markets communications in the company’s news, such as quarterly financial results summaries, cash runway commentary, and notices of participation in healthcare and biotechnology investor conferences. These items are frequently cross-referenced in Avalo’s Form 8-K filings, providing an official record of material events.
By reviewing Avalo Therapeutics news, readers gain insight into how the company is advancing AVTX-009 in hidradenitis suppurativa, how it frames the scientific rationale for IL-1β inhibition in immune-mediated inflammatory diseases, and how it is building its leadership and capital markets presence around this development strategy.
Avalo Therapeutics (Nasdaq: AVTX) said its management will present at two investor conferences in February 2026: a Guggenheim Emerging Outlook Biotech Summit fireside chat on February 11, 2026 at 10:00 AM ET and an Oppenheimer Healthcare Life Sciences fireside chat on February 25, 2026 at 10:00 AM ET.
Live webcasts and replays will be posted under News / Events on the Avalo Therapeutics investor website, with archived webcasts available for at least 30 days.
Avalo Therapeutics (Nasdaq: AVTX) announced inducement equity awards under Nasdaq Listing Rule 5635(c)(4) for three newly hired employees totaling 114,000 nonstatutory stock options.
The Options were granted on Nov 4, Nov 10, and Nov 17, 2025 and break down as 24,000, 72,000, and 18,000 shares respectively. Exercise prices are set equal to the closing price on each grant date. Vesting is over 4 years with 25% vesting at the one-year anniversary and the remainder vesting monthly over 36 months, subject to continued service. Awards are governed by Avalo’s 2025 Inducement Award Plan and individual option agreements.
Avalo Therapeutics (NASDAQ: AVTX) completed enrollment in its Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa (~250 adults) and expects topline data in mid-2026. The company appointed Kevin Lind to the board and added senior leaders in business development and HR. As of September 30, 2025, cash, cash equivalents and short-term investments totaled approximately $111.6 million, which the company said is expected to fund operations into 2028. For Q3 2025, R&D was $13.6M, G&A was $5.6M, and net loss was $30.6M (basic loss per share $2.19).
Avalo Therapeutics (Nasdaq: AVTX) announced management will participate in four investor conferences in November–December 2025 with scheduled fireside chats:
- Guggenheim Healthcare Innovation Conference — Nov 10, 2025 at 4:00 pm ET
- Stifel 2025 Healthcare Conference — Nov 12, 2025 at 2:40 pm ET
- TD Cowen Immunology & Inflammation Summit — Nov 13, 2025 at 9:00 am ET
- Piper Sandler 37th Annual Healthcare Conference — Dec 2, 2025 at 10:30 am ET
Live webcasts and archived replays (available for at least 30 days when provided) will be posted under News / Events in the Investors section at https://ir.avalotx.com.
Avalo Therapeutics (Nasdaq: AVTX) announced completion of enrollment in its Phase 2 LOTUS trial of AVTX-009 for adults with hidradenitis suppurativa (HS).
The trial exceeded its target of 222 patients with approximately 250 patients enrolled. LOTUS is a randomized, double-blind, placebo-controlled Phase 2 study (1:1:1) testing two AVTX-009 dose regimens versus placebo during a 16-week treatment phase. The primary endpoint is the proportion achieving HiSCR75 at Week 16. Secondary measures include HiSCR50/90, IHS4, draining fistula count, AN count, and PGA Skin Pain reductions. Topline data are expected in mid-2026. Trial identifiers: NCT06603077 and www.lotustrial.com.
Avalo Therapeutics (Nasdaq: AVTX), a clinical stage biotech company focused on IL-1β-based treatments, has announced two key leadership appointments. Taylor Boyd joins as Chief Business Officer, bringing 15 years of experience and a track record of executing over $40 billion in M&A and capital markets transactions. Ashley Ivanowicz joins as SVP of Human Resources with 20 years of biotech HR experience.
The appointments come as Avalo prepares for its LOTUS Phase 2 trial of AVTX-009 in hidradenitis suppurativa, with data expected mid-2026. As part of their inducement packages, Boyd and Ivanowicz received 275,000 and 100,000 stock options respectively, vesting over four years with a one-year cliff.
Avalo Therapeutics (Nasdaq: AVTX), a clinical stage biotech company focused on IL-1β-based treatments, has appointed Kevin R. Lind to its Board of Directors. Lind brings over 20 years of leadership experience in capital markets and business development, most notably leading Longboard Pharmaceuticals to a $2.6 billion acquisition by H. Lundbeck A/S in 2024.
The appointment comes as Avalo advances AVTX-009 through Phase 2 LOTUS trial in hidradenitis suppurativa (HS), with topline data expected mid-2026. Throughout his career, Lind has raised over a billion dollars for biotech companies and held key positions at Arena Pharmaceuticals, TPG, and Lehman Brothers.
Avalo Therapeutics (NASDAQ: AVTX), a clinical stage biotech company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, has announced its participation in three upcoming investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference (September 3), the H.C. Wainwright Global Investment Conference (September 9), and the Stifel Virtual Immunology and Inflammation Forum (September 15). All presentations will be available via webcast on the company's investor relations website, with replays accessible for at least 30 days.
Avalo Therapeutics (Nasdaq: AVTX), a clinical-stage biotech company focused on IL-1β-based treatments, reported Q2 2025 financial results and business updates. The company's Phase 2 LOTUS trial for hidradenitis suppurativa (HS) has enrolled over 75% of planned patients, with topline data expected mid-2026.
Financial highlights include $113.3 million in cash and short-term investments as of June 30, 2025, providing runway into 2028. Q2 2025 showed a net loss of $20.8 million ($1.92 per share), compared to net income of $98.5 million in Q2 2024. R&D expenses increased by $9.5 million to $14.1 million, primarily due to LOTUS trial costs.
The company strengthened its leadership by appointing Rita Jain, M.D. to the Board of Directors, bringing valuable experience in clinical development and regulatory strategy.
FAQ
What is the current stock price of Avalo Therapeutics (AVTX)?
What is the market cap of Avalo Therapeutics (AVTX)?
